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Abstract
Chronic oxidative stress (OS), a major mechanism of chronic obstructive pulmonary disease (COPD), may cause significant
damage to DNA. Poly(ADP-ribose) polymerase (PARP)-1 is rapidly activated by OS-induced DNA lesions. However, the
degree of DNA damage along with the evolution of COPD is unclear. In peripheral blood mononuclear cells of non-smoking
individuals, non-obstructive smokers, patients with COPD of all stages and those with COPD exacerbation, we evaluated
DNA damage, PARP activity and PARP-1 mRNA expression using Comet Assay IV, biotinylated-NAD incorporation assay and
qRT-PCR, respectively and subjected results to ordinal logistic regression modelling. Adjusted for demographics, smoking-
related parameters and lung function, novel comet parameters, tail length/cell length ratio and tail migration/cell length
ratio, showed the greatest increase along the study groups corresponding to the evolution of COPD [odds ratio (OR) 7.88,
95% CI 4.26–14.57; p,0.001 and OR 3.91, 95% CI 2.69–5.66; p,0.001, respectively]. Analogously, PARP activity increased
significantly over the groups (OR= 1.01; 95%; p,0.001). An antioxidant tetrapeptide UPF17 significantly reduced the PARP-
1 mRNA expression in COPD, compared to that in non-obstructive individuals (p = 0.040). Tail length/cell length and tail
migration/cell length ratios provide novel progression-sensitive tools for assessment of DNA damage. However, it remains
to be elucidated whether inhibition of an elevated PARP-1 activity has a safe enough potential to break the vicious cycle of
the development and progression of COPD.
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Introduction
Of the major mechanisms of chronic obstructive pulmonary
disease (COPD), oxidative stress (OS) resulting from direct effects
of smoking, but also from persistent inflammation, causes oxidative
damage to important biomolecules, including DNA [1–3]. Spill-
over of the OS to the circulation is associated with a significant
systemic disease in COPD [4,5]. The resulting fall in antioxidant
capacity of blood cells could therefore be regarded as a measure of
OS in COPD.
Systemic inammation and OS suggest a role for the nuclear
enzyme poly(ADP-ribose) polymerase (PARP)-1 (E.C.2.4.2.30) in
the pathophysiology of COPD [6]. PARP-1, a member of the
PARP superfamily of 18 enzymes, is responsible for more than
90% of the cellular poly(ADP-ribosyl)ation capacity [6]. PARP-1 is
activated by reactive oxygen species (ROS)-induced DNA strand
breaks, upon which it forms extensive poly(ADP-ribose) polymers
from its substrate NAD+ [7]. In extensive DNA damage, PARP-1
activation causes depletion of NAD+ leading to cell death via
reduced glycolysis and mitochondrial respiration [8]. Unlike that
on the systemic effects of COPD in general, the data on DNA
damage and expression of PARP-1 are inconsistent.
Animal models have shown that PARP-1 activation contributes
significantly to the pathophysiology of chronic inflammatory
diseases like asthma [9–11], diabetes [8], rheumatoid arthritis
[12] and chronic colitis [13]. An elevation of PARP-1 in murine
hippocampus could serve as proof of PARP-1 as a marker of
systemic inflammation [14]. It has been shown, that PARP-1
activity is increased in peripheral blood lymphocytes in patients
with COPD [7]. However, we currently tested the hypothesis that
the expression of PARP-1 and PARP activity in human peripheral
blood mononuclear cells (PBMC) are related to the progression of
COPD. In parallel, we employed and developed further comet
assay as a sensitive method for detection of DNA strand breaks,
alkali-labile sites and delayed repair sites [15].
As far COPD is accompanied by systemic OS, the effect of
novel tetrapeptide analogue of glutathione (GSH), UPF17 (4-
methoxy-L-tyrosinyl-a-L-glutamyl-L-cysteinyl-glycine) on the
PARP-1 activity through changing mRNA expression of PARP-
1 was measured.
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Subjects and Methods
Study Subjects
All participants, recruited from the Department of Pulmonary
Medicine, Tartu University Hospital, Tartu, Estonia, were
selected to create seven study groups: 1) non-obstructive never-
smoking control individuals with normal lung function, 2) current
smokers or ex-smokers with normal lung function matching the
COPD patients for their demographics and smoking history and
habits, 3) four patients groups formed by the four stages of stabile
COPD (I-IV) according to the Global Initiative for COPD
(GOLD) Guidelines, based on the post-bronchodilator forced
expiratory volume in one second (FEV1) and 4) patients with a
COPD exacerbation according to the GOLD criteria requiring
hospitalisation (table 1) [16]. All patients with COPD had their
post-bronchodilator FEV1/forced vital capacity ratio ,0.7 and all
showed ,12% improvement in FEV1 compared with the pre-
bronchodilator value. A current smoker was defined as a person,
who currently smoked at least one cigarette per day, whereas an
ex-smoker was defined as a person, who had quitted smoking for
$6 month prior to the study. The exclusion criteria included
pneumonia, bronchiectasis and any malignancy and all subjects
except for those with COPD exacerbation had to be free of viral
respiratory infections within the last 2 months. Patients were
treated according to the severity of the disease and in accordance
with the GOLD guidelines. The study was approved by the Ethics
Committee on Human Research of the University of Tartu.
Written informed consent was obtained from all participants.
Mononuclear Cell Extraction from Peripheral Blood
PBMC were separated in BD Vacutainer CPT tubes (Becton
Dickinson, Franklin Lakes, NJ, USA), by centrifugation at 15006g
for 21 min at 20uC. Isolated PBMC were washed twice with
phosphate-buffered saline (PBS). 200 ml of PBMC suspension
(66106 cells/ml) were frozen down in 10% dimethyl sulfoxide
(DMSO) and RPMI-1640 [including 10% foetal calf serum (FCS)
and 1% penicillin/streptomycin] for the comet assay and
measurement of PARP activity. The remaining PBMC were
cultured in RPMI-1640 medium for the PARP-1 mRNA expres-
sion studies.
Comet Assay
PBMC were embedded with 0.5% low melting point agarose
(Gibco by Life Technologies, Carlsbad, CA, USA) in distilled
water and the mixture was added to a microscope slide, pre-coated
with 1% of normal melting point agarose in distilled water, and
covered with a coverslip. The slide was placed briefly to 4uC for
the agarose to achieve solidify. The slides were then immersed in
lysis solution [2.5 M NaCl, 100 mM ethylenediaminetetraacetic
acid (EDTA) and 10 mM Tris, pH 10.0] containing freshly added
1% triton X-100 and 10% DMSO for at least 1 h at 4uC.
Subsequently, the slides were incubated in freshly prepared
alkaline buffer (300 mM NaOH and 1 mM EDTA, pH.13) for
40 min for DNA unwinding and electrophoresed in the same
buffer. The conditions for electrophoresis were 30 min at 300 mA
and 25 V. Following electrophoresis, slides were neutralized with
PBS, washed in distilled water and 70% ethanol and dried
overnight. The gels were stained for DNA with 1 mg/ml 49,6-
diamidino-2-phenylindole dihydrochloride solution in distilled
water and air-dried. Images of 100 randomly selected cells (50
cells from each of two replicate slides) were taken with Zeiss
Axiolab microscope (Carl Zeiss, Oberkochen, Germany) and
analysed using Comet Assay IV software (Perceptive Instruments
Ltd., Suffolk, UK). All standard parameters originally provided by
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the Comet Assay IV were used. In addition, a set of novel
parameters were tested for their ability to more precisely
characterise the DNA damage by the progression of COPD: tail
moment length, extent tail moment, cell length, tail length/cell
length ratio and tail migration/cell length ratio. Tail moment
length shows the distance from the centre of the head to the centre
of the tail, extent tail moment was calculated by dividing DNA %
in the tail by the tail length and cell length shows the distance from
the beginning of the head until the end of the tail.
Detection of PARP Activity
PARP activity was measured using 6-biotin-17-nicotinamide-
adenine-dinucleotide (bio-NAD+), as previously described [17].
PBMC were cultured on poly-L-lysine-coated coverslips in RPMI
medium, supplemented with 10% FCS. After 20 min incubation
allowing cells to attach to slides, the medium was removed and
replaced with PARP reaction buffer [56 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, 28 mM KCl, 28 mM NaCl, 2 mM
MgCl2, pH 8.0, complemented with 0.01% digitonin and 250 mM
biotinylated NAD+ immediately before use]. After 60-min
incubation at 37uC, the cells were fixed at -20uC in 95% ethanol
followed by 10% trichloroacetic acid. The coverslips were rinsed
in PBS and endogenous peroxidase was blocked by 0.5% H2O2/
methanol for 15 min. After rinses with PBS, the coverslips were
blocked in 1% bovine serum albumin/PBS for 30 min, followed
by rinses in PBS–Triton X-100 (0.1%). Incorporated biotin was
detected by streptavidin–peroxidase (diluted 1:100 in PBS–Triton
X-100) for 30 min. Coverslips were washed with PBS–Triton X-
100 and colour was developed with cobalt-enhanced nickel-3,39-
diaminobenzidine substrate. The coverslips were mounted with
glycerol on slides and viewed under a Zeiss Axiolab microscope
(Carl Zeiss). The pictures were taken with a Zeiss Axiocam digital
camera (Carl Zeiss) and analysed using AlphaView Software
(ProteinSimple, Santa Clara, CA, USA).
Measurement of PARP-1 mRNA Expression
The PBMC suspension was divided into halves with one part
cultured in the presence of 500 nM UPF17 and the other without
UPF17 that served as a control in RPMI-1640 medium (includes
10% FCS and 1% penicillin/streptomycin). After 12 hours, RNA
was extracted from PBMC with the Trizol method according to
manufacturer’s protocol (Invitrogen by Life Technologies) and
stored at –80uC until cDNA synthesis. cDNA was synthesized with
reverse transcriptase reaction, from total RNA (250 ng) using the
SuperScript III enzyme (Invitrogen by Life Technologies),
according to manufacturer’s instructions.
The gene expression levels were detected using the TaqMan-
qRT-PCR method (ABI Prism 7900HT Sequence Detection
System, Applied Biosystems by Life Technologies) using
Hs00242302_m1 for PARP-1 and hypoxanthine phosphoribosyl-
transferase-1 (HPRT-1) as house keeper gene (both from Applied
Biosystems by Life Technologies). All reactions were carried out in
quadruplicates. The comparative Ct method (DCt value) was used
for quantification of mRNA, where the amount of target transcript
was normalized to the level of endogenous HPRT-1.
Statistical Analysis
The equality of the baseline data across the study groups was
evaluated with Kruskal-Wallis test in numeric variables and
Pearson’s chi-square test in nominal variables. Associations of the
comet assay parameters, as well as the PARP-1 expression and
PARP activity with the presumably increasing degree of impair-
ment from healthy never-smokers through non-obstructive smok-
ers, stable COPD patients of GOLD stages I-IV to patients with
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COPD exacerbation, were assessed with ordinal logistic regression
analysis with calculating the odds ratios (OR) and their 95%
confidence intervals (95% CI). Because of the very high
collinearity between the comet assay indices due to their
derivation, the comet parameters were not simultaneously
included into the multivariate model. Instead, the ability of each
of the comet assay parameters to indicate the increasing degree of
DNA impairment throughout the study groups was assessed
separately, though each of them was adjusted for age, gender,
body mass index (BMI), lung function (FEV1% predicted), pack-
years of smoking and status of a current smoker. The analyses of
PARP-1 expression and PARP activity were adjusted similarly.-
Mann-Whitney U-Test was performed to determine the difference
between the COPD patients and non-COPD individuals for the
effect of UPF17 on PARP-1 mRNA expression level. p-values
below 0.05 were considered to designate statistical significance. All
statistical analyses were performed with the Statistical Package for
Social Sciences (SPSS, version 17.0, SPSS Inc., Chicago, IL, USA)
software.
Results
Study Subjects
Different cohorts were used to measure the DNA damage by
comet assay and PARP activity (table 1) and the PARP-1 mRNA
expression level (table 2). Amongst the patients, who were chosen
for DNA damage and PARP activity analysis, there was a
difference for smoking history because one patient with COPD
exacerbation had a smoking history of 116 pack-years.
DNA Damage, PARP Activity and Expression of PARP-
1 mRNA in PBMC
After adjustment for age, gender, BMI, smoking history (pack-
years), status of a current smoker and FEV1% predicted, of the
Comet IV standard parameters, olive tail moment, DNA % in the
tail, head length, tail length and tail migration increased
significantly (OR.1.0, p,0.05), whereas DNA % in the head,
as well as mean grey level and total intensity decreased
significantly (OR,1.0, p,0.05) along the order from healthy
control individuals through non-obstructive smokers, patients with
increasing stage of stable COPD to those with exacerbation of
COPD (table 3, figure 1). Of the derived parameters, tail moment
length, extent tail moment and cell length, as well as the novel
parameters tail length to cell length ratio and tail migration to cell
length ratio also increased significantly to designate escalation to
the next group in our study (OR.1.0, p,0.05), (table 3, figure 1).
In particular, the comet parameters from PBMC that had the
highest OR to reflect the DNA changes along with the evolution of
COPD turned out to be the novel parameters tail length/cell
length and tail migration/cell length ratios. One unit increase in
tail length/cell length ratio and tail migration/cell length ratio was
associated with a 7.88-fold (95% CI 4.26–14.57, p,0.001) and a
3.91-fold (95% CI 2.69–5.66, p,0.001) higher probability,
respectively, of progressing into the next group of individuals
(figure 1, table 3).
PARP activity was a significant factor associated with escalation
into the next group in our study (OR 1.014, 95% CI 1.006–1.023,
p,0.001) (table 4, figure 2). Unlike PARP activity, PARP-
Figure 1. The level of damage to DNA in peripheral blood mononuclear cells. a) Evaluation by comet assay. b) Tail migration/cell length
ratio measured with Comet Assay IV. c) Tail length/cell length ratio measured with Comet Assay IV. The study groups are designated as follows: (1)
non-smoking, non-obstructive control individuals (n = 7); (2) non-obstructive smokers (n = 4); (3) patients with mild chronic obstructive pulmonary
disease (COPD) (n = 3); (4) patients with moderate COPD (n= 7); (5) patients with severe COPD (n= 5); (6) patients with very severe COPD (n= 4); (7)
patients with COPD exacerbation requiring hospitalisation (n = 6). Presented as mean 6 SEM.
doi:10.1371/journal.pone.0070333.g001
DNA Damage and PARP Activity in COPD
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Table 3. Changing DNA damage in peripheral blood mononuclear cells by Comet Assay IV parameters from never-smoking
control individuals through current smokers or ex-smokers with normal lung function and patients with stabile chronic obstructive
pulmonary disease (COPD) of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I-IV to patients with a COPD
exacerbation, evaluated with ordinal logistic regression analysis.
Crude Adjusted*
Parameter OR (95% CI) p-value OR (95% CI) p-value
Standard Comet Assay IV parameters
Olive tail moment 1.093 (1.074–1.112) ,0.001 1.047 (1.025–1.069) ,0.001
Head DNA % 0.985 (0.982–0.988) ,0.001 0.992 (0.988–0.996) ,0.001
Tail DNA % 1.018 (1.015–1.021) ,0.001 1.008 (1.003–1.012) ,0.001
Head length 1.010 (1.002–1.018) 0.019 1.017 (1.005–1.029) ,0.001
Tail length 1.053 (1.047–1.059) ,0.001 1.039 (1.030–1.047) ,0.001
Tail migration 1.050 (1.044–1.056) ,0.001 1.034 (1.026–1.042) ,0.001
Mean grey level 1.013 (1.010–1.017) ,0.001 0.995 (0.990–,1.000) 0.047
Total area 1.0002 (,1.000–1.0005) 0.051 1.0003 (0.9999–1.0006) 0.14
Total intensity ,1.000 (,1.000–.1.000) 0.53 ,1.000 (,1.000–,1.000) ,0.001
Width 1.001 (0.993–1.010) 0.75 1.009 (0.997–1.021) 0.15
Derived parameters
Tail moment length 1.096 (1.084–1.108) ,0.001 1.079 (1.063–1.096) ,0.001
Extent tail moment 1.0005 (1.0004–.1.0006) ,0.001 1.0003 (1.0002–1.0004) ,0.001
Cell length 1.047 (1.041–1.052) ,0.001 1.039 (1.031–1.047) ,0.001
Tail length/cell length# 22.459 (14.171–35.595) ,0.001 7.880 (4.264–14.565) ,0.001
Tail migration/cell length# 7.583 (5.744–10.012) ,0.001 3.905 (2.694–5.661) ,0.001
*Adjusted for age, gender, body mass index, smoking history (pack-years), status of a current smoker and forced expiratory volume in one second % predicted. #Novel
derived parameters.
doi:10.1371/journal.pone.0070333.t003
Figure 2. Poly(ADP-ribose) polymerase (PARP) activity and PARP-1 mRNA expression in peripheral blood mononuclear cells. a)
PARP activity using biotinylated-NAD incorporation assay. b) PARP-1 mRNA expression levels measured with qRT-PCR. The study groups are
designated as follows: (1) non-smoking, non-obstructive control individuals (n = 7 and n=10 for patients involved in PARP activity and PARP-1 mRNA
expression analysis, respectively); (2) non-obstructive smokers (n = 4 and n=12); (3) patients with mild chronic obstructive pulmonary disease (COPD)
(n = 3 and n=4); (4) patients with moderate COPD (n= 7 and n= 14); (5) patients with severe COPD (n= 5 and n=24); (6) patients with very severe
COPD (n= 4 and n= 21); (7) patients with COPD exacerbation requiring hospitalisation (n = 6 and n= 22). Presented as mean 6 SEM.
doi:10.1371/journal.pone.0070333.g002
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1 mRNA expression level did not show an ordinal change
accordingly to the groups in our study (table 4, figure 2).
Effect of UPF17 on the Expression of PARP-1 mRNA
UPF17 had a stronger PARP-1 mRNA expression level
lowering effect amongst patients with COPD, as compared to
that amongst non-obstructive individuals (non-obstructive non-
smokers and non-obstructive smoking individuals) (p = 0.040)
(figure 3).
Discussion
After adjustment for demographic variables, BMI, smoking-
related indices and lung function, in the PBMC, the common
Comet Assay IV parameters indicative of DNA damage, such as
tail length, tail migration, olive tail moment and DNA % in the
tail, showed a significant positive dependence on progression
throughout the scale from healthy non-smoking controls to severe
exacerbations of COPD. Formerly, the issue of stage- or
progression-dependence of the DNA damage in COPD has
remained controversial. Ceylan et al. showed an increased DNA
damage in peripheral blood mononuclear leukocytes in patients
with COPD [1], but using the same technique, Maluf et al. did not
detect a correlation between the increased DNA damage in
PBMC and COPD severity [18]. The major difference between
the current study and those conducted by Ceylan et al. and Maluf
et al. was that in the current one, a special software (Comet Assay
IV) was used to analyse at least 10 different variables of the comet
assay instead of visual scoring of the tail intensity only.
Furthermore, in our study 7 groups were analysed using ordinal
logistic regression to test for the progressing DNA injury from non-
smoking control and non-obstructive smokers through the four
COPD stages to severe COPD exacerbation. The DNA damage
along with PARP activity and PARP-1 mRNA expression has not
been investigated formerly in this way. In-vitro studies have shown
relations of PARP activity and cigarette smoke [19,20]. Also,
differential activation of PARP in PBMC from controls and
COPD patients has been shown previously [7], but in-vivo studies
on the relationships between PARP activity and COPD progres-
sion have not been performed before. Not less importantly, all
variables indicative of DNA damage were adjusted for parameters
like age, gender, BMI, smoking habits and lung function. In the
context that COPD is a disease of systemic senescence [21], the
results adjusted for the demographic and clinical parameters point
out that the increase in DNA damage is likely to increase
accordingly to the advancement of the OS and inflammation from
non-smoking controls up to COPD exacerbation, rather than
caused by age, by fall in FEV1% or by cigarette smoke (CM) alone.
Adjustment to gender might be of particular importance, as the
PBMC PARP activity has been shown to be significantly lower
amongst female subjects compared with male subjects [22].
Moreover, according to rodent [23] and porcine [24] models,
the regulation of PARP has been reported to be more profound in
males than in females. In addition to the variables provided by the
Comet Assay IV, 5 new parameters were introduced and found to
reflect the relationship between DNA damage and the progression
of the disease even better. Out of the novel or newly introduced
parameters, the tail length/cell length ratio and tail migration/cell
length ratio were found to show the highest ORs with the
development and progression of COPD up to COPD exacerba-
tion. A one unit increase in tail length/cell length ratio and tail
migration/cell length ratio was associated with a 7.88-fold or 3.91-
fold higher probability, respectively, for the process progressing to
the next stage and therefore can appear most suitable to describe
the DNA damage in PBMC over the evolution of COPD. This is
the first report to show that these new parameters are most
sensitive for the advancement of COPD and to suggest the tail
length/cell length ratio and the tail migration/cell length ratio as
new precision tools for independent assessment of the DNA
damage in smokers and in patients with COPD.
Along with the comet assay indices, the current study revealed a
strong relationship between the evolution of COPD and PARP
activity in PBMC. These data suggest an intensified DNA repair
occurring in PBMC of patients with higher COPD stages and adds
a valuable adjunct to understanding of the systemic component of
COPD. PARP activity was somehow heightened amongst the non-
obstructive smokers, as compared to both the non-smoking
Table 4. Changing poly(ADP-ribose) polymerase (PARP) activity and PARP-1 mRNA expression in peripheral blood mononuclear
cells from never-smoking control individuals through current smokers or ex-smokers with normal lung function and patients with
stabile chronic obstructive pulmonary disease (COPD) of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages I-
IV to patients with a COPD exacerbation, evaluated with ordinal logistic regression analysis.
Crude Adjusted*
Parameter OR (95% CI) p-value OR (95% CI) p-value
PARP activity 1.049 (1.043–1.056) ,0.001 1.014 (1.006–1.023) ,0.001
PARP-1 mRNA expression 4.510 (0.448–45.365) 0.20 4.735 (0.378–59.298) 0.23
*Adjusted for age, gender, body mass index, smoking history (pack-years), status of a current smoker and forced expiratory volume in one second % predicted.
doi:10.1371/journal.pone.0070333.t004
Figure 3. Mann-Whitney U-Test showing a significant down-
regulation of the poly(ADP-ribose) polymerase-1 mRNA ex-
pression in peripheral blood mononuclear cells from patients
with chronic obstructive pulmonary disease (n=85) by an
antioxidant tetrapeptide UPF17 in comparison with that in
non-obstructive individuals (n =22) (p =0.040).
doi:10.1371/journal.pone.0070333.g003
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controls on one hand and to patients with mild COPD on the
other (table 4, figure 2). This may indicate that those smokers, who
do not develop COPD, are still sensitive to various antioxidant
influences than do COPD patients, at least those with a milder
disease. This suggests that although PARP is a very important
player in the DNA repair, it does not represent the only pathway
to prevent smokers from developing COPD. In mammalian cells,
the basal enzymatic activity of PARP is very low, but oxidative and
nitrosative stress can trigger DNA strand breakage, which in turn
abruptly stimulates the PARP-1 activity [20,25–27]. Moderate
activation of PARP is of physiological importance and could be
beneficial via facilitating the DNA repair. However, over-
activation of PARP is connected to numerous pathological
conditions associated with oxidative and nitrosative stress,
including COPD [28]. In particular, in parallel with energy
depletion by the cells caused by PARP over-activation, PARP
contributes to the synthesis of inflammatory mediators including
cytokines, chemokines and enzymes like inducible nitric oxide
synthase, but also up-regulates expression of pro-inflammatory
genes, which leads to augmented inflammation [6]. Thus, the
DNA damage caused by chronic OS as one of the main
mechanisms of COPD can activate PARP. As a consequence,
systemic PARP over-activation may play an important role by up-
regulating the expression of pro-inflammatory genes in COPD
[29,30] leading to a vicious circle of consecutively increased OS
and inflammation. In this light, one could speculate that the over-
activation of PARP can be one of the intermediate mechanisms for
the abnormally augmented inflammation in COPD [31]. If true,
inhibition of PARP activity could provide protection against OS-
related inflammation and thereby afford therapeutic benefits in
COPD [32,33].
Our study showed that UPF17, a non-toxic and ,3000-fold
better hydroxyl radical scavenger than GSH [34,35], has a
significant inhibitory effect on PARP-1 mRNA expression in
patients with COPD, compared to that in non-obstructive
individuals. Our latest experiments on HepG2 cells suggested that
the activity of UPF17 is mediated via the nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) (unpublished data). Although, inhibiting
PARP can have anti-inflammatory effects, inhibiting PARP in a
greater degree reduces DNA repair in cells [36], which can be
considered as a side effect in the context of COPD. Collectively,
the clinical significance of PARP-1 down-regulation remains
elusive.
Prospective nature, inclusion of people from healthy controls
through non-obstructive smokers to severe exacerbation of COPD
into ordinary logistic regression models adjusted for major
demographic, clinical and smoking-related parameters can be
considered as strengths of the study. Small and unequal study
groups and different populations for comet assay and assessment of
PARP-1 mRNA expression are clear limitations.
Taken together, the present results show that COPD is a
systemic disease and that DNA damage and PARP activation in
PBMC are related both to the progression of COPD, but also to its
exacerbation. The newly derived comet assay parameters (tail
length/cell length ratio and tail migration/cell length ratio) can
better reflect the changes occurring along with the evolution of
COPD than the standard parameters that were used up to now.
Furthermore, UPF17 was effective in modulating the expression of
PARP-1 mRNA. However, it remains to be elucidated whether a
modest inhibition of PARP-1 may have a safe enough potential to
break the vicious cycle of the development and progression of
COPD.
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